Nexiclon Xr
Loading...Nexiclon Xr Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
NEXICLON XR is indicated in the treatment of hypertension. NEXICLON XR may be employed alone or concomitantly with other antihypertensive agents.
History
There is currently no drug history available for this drug.
Other Information
NEXICLON XR (clonidine) Extended-Release Oral Suspension is available for oral administration in one extended-release dose strength 0.09 mg/mL. The 0.09 mg/mL suspension is equivalent to 0.1 mg/mL of immediate-release clonidine hydrochloride.
Clonidine hydrochloride, a centrally active alpha-adrenergic agonist, is an imidazoline derivative and exists as a mesomeric compound. The chemical name is 2-(2.6-dichlorophenylamino)-2-imidazoline hydrochloride. The following is the structural formula:
[IC]
C9H9Cl2N3·HCl Mol. Wt. 266.56
Clonidine hydrochloride is an odorless, bitter, white crystalline substance soluble in water and alcohol.
The inactive ingredients are: citric acid anhydrous, flavor, glycerin, high fructose corn syrup, methylparaben, modified food starch, polyvinyl acetate, polysorbate 80, povidone, propylparaben, purified water, sodium polystyrene sulfonate, sucrose, triacetin, and xanthan gum.
Sources
Nexiclon Xr Manufacturers
-
Tris Pharma, Inc.
![Nexiclon Xr (Clonidine) For Suspension, Extended Release [Tris Pharma, Inc.]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Nexiclon Xr | Tris Pharma, Inc.
Maintenance dose: Further increments of 0.09 mg (1 mL) once daily may be made at weekly intervals if necessary until the desired response is achieved. The therapeutic doses most commonly employed have ranged from 0.17 mg to 0.52 mg once daily (2.2)The dose of NEXICLON XR must be adjusted according to the patient's individual blood pressure response. The following is a general guide to its administration in adults.
2.1 Initial DoseDosing with NEXICLON XR should be initiated 0.17 mg (2 mL) once daily. Elderly patients may benefit from a lower initial dose [see Use is Specific Populations (8.4)]. Initial dose is recommended to be administered at bedtime.
2.2 Maintenance DoseFurther increments of 0.09 mg (1 mL) once daily may be made at weekly intervals if necessary until the desired response is achieved. The therapeutic doses most commonly employed have ranged from 0.17 mg (2 mL to 0.52 mg (6 mL) once daily.
NEXICLON XR was studied at doses of 0.17 to 0.52 mg to 0.52 mg (2 to 6 mL) once daily. Doses higher than 0.52 mg (6 mL) per day were not evaluated and are not recommended.
2.3 Patients Currently Using Clonidine Hydrochloride Immediate Release TabletsThe recommended does of NEXICLON XR for patients who are currently taking clonidine hydrochloride immediate-release tablets is provided in the table below.
NEXICLON XR (Clonidine Extended Release)Oral Suspension Equivalent dose of Clonidine HCl Immediate-Release Tablets Initial Dose 0.17 mg (2 mL) once daily 0.1 mg twice daily Maintenance Dose Titration Increments 0.09 mg (1 mL) once daily 0.05 mg twice daily Common Doses Used for Blood Pressure Effect 0.17 mg (2 mL) once daily 0.1 mg twice daily 0.34 mg (4 mL) once daily 0.2 mg twice daily 0.52 mg (6 mL) once daily 0.3 mg twice daily 2.4 Renal ImpairmentAdjust dosage according to the degree of impairment. In patients with end stage kidney disease on maintenance dialysis, start at 0.09 mg (1 mL) per day and up-titrate slowly to minimize dose related adverse events.
Monitor patients carefully, especially for bradycardia, sedation and hypotension. Only a minimal amount of clonidine is removed during routine hemodialysis.
In patients with moderate to severe kidney impairment not undergoing dialysis, initiate clonidine at the same dose as for patients without renal impairment. Up-titrate slowly and monitor for dose-related adverse events.
Login To Your Free Account